Quest Diagnostics stock has produced strong share price gains in recent years, yet its current US$234.40 price still sits below an intrinsic value estimate from a Discounted Cash Flow (DCF) model that points to meaningful upside.

• The stock has returned 87.1% over the past 3 years, which puts recent valuation questions front and center for Quest Diagnostics.
• Expectations for steady cash flow generation from diagnostic testing can support the current valuation. At the same time, any pressure on testing volumes or reimbursement rates may weigh on what investors are willing to pay.
• Quest Diagnostics screens as undervalued in 5 of 6 checks, and that high value score suggests the broader set of valuation measures leans cheap overall.

The issue now is whether the market is still underpricing Quest Diagnostics or if the recent share price strength has already captured most of the valuation upside implied by the intrinsic value estimate.

Does Quest Diagnostics Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach values Quest Diagnostics based on the cash it is expected to generate for shareholders. The model uses latest twelve month free cash flow of about US$1.40b and assumes this cash generation grows over time rather than shrinking. On that basis, the 2 Stage Free Cash Flow to Equity model points to an estimated intrinsic value of about $348 per share.

Set against the current share price of $234.40, the DCF output implies Quest Diagnostics trades at roughly a 32.6% discount to this intrinsic value estimate. That gap suggests the market price may not fully reflect the cash flows currently projected for the business, while other factors such as testing volumes, reimbursement trends and execution risk can still influence how the stock trades.

On balance, the discounted cash flow workup indicates Quest Diagnostics stock appears undervalued at today’s price based on these assumptions.

Our Discounted Cash Flow (DCF) analysis suggests Quest Diagnostics is undervalued by 32.6%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Is Quest Diagnostics Fairly Priced on Earnings?

P/E is a useful cross check for Quest Diagnostics because earnings are a key driver of how investors typically value established healthcare service providers. On this measure, Quest Diagnostics currently trades on a P/E of about 24.5x, which sits slightly below the wider healthcare industry average of roughly 25.3x and also below the peer group average of about 25.8x. That puts the stock close to the middle of the pack rather than standing out as aggressively priced in either direction.

A more tailored fair P/E for Quest Diagnostics, which factors in its scale, margins, industry positioning and risk profile, sits around 26.3x. Compared with the current 24.5x multiple, this model points to only a modest gap. The market price therefore appears broadly aligned with what this framework suggests investors might pay for the company’s earnings today.

Overall, Quest Diagnostics appears roughly fairly valued on its P/E multiple based on these benchmarks.

The Quest Diagnostics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Quest Diagnostics pick up where the valuation work leaves off and focus on what would need to be true about the company’s future growth, margins and earnings for the stock to be worth materially more or less than today’s price. Each narrative sets out a fair value as an explicit, testable thesis about Quest Diagnostics' business so you can watch how that view holds up over time on the Community page.

You can add your voice to the Simply Wall St community by sharing a Narrative on Quest Diagnostics that lays out a clear, number driven view on where its growth, margins and execution go from here. Set out your thesis, track it against future results and see how your take on Quest Diagnostics' valuation holds up over time.

Do you think there's more to the story for Quest Diagnostics? Head over to our Community to see what others are saying!

The Bottom Line

Quest Diagnostics screens as undervalued on the Discounted Cash Flow (DCF) intrinsic value estimate, while its P/E multiple sits close to what peers and a tailored fair ratio suggest is about right. The strong overall valuation checks hint that the current price still builds in some caution about future cash flows rather than full confidence. The key question from here is whether Quest Diagnostics can sustain its cash generation and protect margins and reimbursement levels, which would help determine if the present discount reflects opportunity or a fair allowance for those risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.